Ixekizumab: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:
|drugClass=humanized anti-interleukin-17 monoclonal antibody
|drugClass=humanized anti-interleukin-17 monoclonal antibody
|indicationType=treatment
|indicationType=treatment
|indication=of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
|indication=of adults with moderate-to-severe [[plaque psoriasis]] who are candidates for systemic therapy or [[phototherapy]].
|adverseReactions=injection site reactions, upper respiratory tract infections, nausea, and tinea infections (≥1%).
|adverseReactions=[[injection site reaction]]s, [[upper respiratory tract infection]]s, [[nausea]], and [[tinea]] infections (≥1%).
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=*Administer by subcutaneous injection.
|fdaLIADAdult======Dosage=====
*Recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
Ixekizumab is administered by [[subcutaneous injection]]. The recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
 
=====Tuberculosis Assessment Prior to Initiation of Ixekizumab=====
 
Evaluate patients for [[tuberculosis]] (TB) infection prior to initiating treatment with Ixekizumab.
 
=====Important Administration Instructions=====
 
There are two presentations for Ixekizumab (i.e., [[autoinjector]] and prefilled [[syringe]]).
 
Ixekizumab is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in [[subcutaneous injection]] technique using the [[autoinjector]] or prefilled [[syringe]]. Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, [[erythema]]tous, [[induration|indurated]] or affected by [[psoriasis]]. Administration of Ixekizumab in the upper, outer arm may be performed by a caregiver or healthcare provider.
 
If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
 
=====Preparation for Use of Ixekizumab [[Autoinjector]] and Prefilled [[Syringe]]=====
 
Before injection, remove Ixekizumab [[autoinjector]] or Ixekizumab prefilled [[syringe]] from the refrigerator and allow Ixekizumab to reach room temperature (30 minutes) without removing the needle cap.
 
Inspect Ixekizumab formulation visually for particulate matter and discoloration prior to administration. Ixekizumab formulation is a clear and colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow). Ixekizumab formulation does not contain preservatives, therefore discard any unused product remaining in the [[autoinjector]] or prefilled [[syringe]].
 
Instruct patients using the [[autoinjector]] or prefilled [[syringe]] to inject the full amount (1 mL), which provides 80 mg of Ixekizumab, according to the directions.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ixekizumab in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ixekizumab in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ixekizumab in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ixekizumab in adult patients.
|fdaLIADPed=FDA Package Insert for Ixekizumab contains no information regarding Pediatric Indications and Dosage.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ixekizumab in pediatric patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ixekizumab in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ixekizumab in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ixekizumab in pediatric patients.
|contraindications=Ixekizumab is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients
|contraindications=Ixekizumab is contraindicated in patients with a previous serious [[hypersensitivity reaction]], such as [[anaphylaxis]], to ixekizumab or to any of the excipients.
|warnings=*Infections
|warnings======Infections=====
 
Ixekizumab may increase the risk of [[infection]]. In [[clinical trial]]s, the Ixekizumab treated group had a higher rate of infections than the [[placebo]] group (27% vs. 23%). [[Upper respiratory tract infection]]s, [[oral candidiasis]], [[conjunctivitis]] and [[tinea]] infections occurred more frequently in the Ixekizumab treated group than in the [[placebo]] group.
:*TALTZ may increase the risk of infection. In clinical trials, the TALTZ group had a higher rate of infections than the placebo group (27% vs. 23%). Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the TALTZ group than in the placebo group [see Adverse Reactions (6.1)].


Instruct patients treated with TALTZ to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TALTZ until the infection resolves.
Instruct patients treated with Ixekizumab to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue Ixekizumab until the infection resolves.


*Pre-treatment Evaluation for Tuberculosis
=====Pre-treatment Evaluation for [[Tuberculosis]]=====
:*Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TALTZ. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering TALTZ. Consider anti-TB therapy prior to initiating TALTZ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving TALTZ should be monitored closely for signs and symptoms of active TB during and after treatment.
Evaluate patients for [[tuberculosis]] (TB) infection prior to initiating treatment with Ixekizumab. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Ixekizumab. Consider [[tuberculosis medical therapy|anti-TB therapy]] prior to initiating Ixekizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving Ixekizumab should be monitored closely for signs and symptoms of active TB during and after treatment.


*Hypersensitivity
=====Hypersensitivity=====
:*Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the TALTZ group in clinical trials. If a serious hypersensitivity reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy [see Adverse Reactions (6.1)].
Serious [[hypersensitivity]] reactions, including [[angioedema]] and [[urticaria]] (each ≤0.1%), occurred in the Ixekizumab group in [[clinical trial]]s. If a serious [[hypersensitivity reaction]] occurs, discontinue Ixekizumab immediately and initiate appropriate therapy.


*Inflammatory Bowel Disease
=====Inflammatory Bowel Disease=====
:*Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than the placebo group (0%) during the 12-week, placebo-controlled period. During TALTZ treatment, monitor for onset or exacerbation of inflammatory bowel disease.
[[Crohn's disease]] and [[ulcerative colitis]], including exacerbations, occurred at a greater frequency in the Ixekizumab group ([[Crohn's disease]] 0.1%, [[ulcerative colitis]] 0.2%) than the [[placebo]] group (0%) during the 12-week, [[placebo]]-controlled period. During Ixekizumab treatment, monitor for onset or exacerbation of [[inflammatory bowel disease]].


*Immunizations
=====Immunizations=====
:*Prior to initiating therapy with TALTZ, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TALTZ. No data are available on the response to live or inactive vaccines.
Prior to initiating therapy with Ixekizumab, consider completion of all age appropriate [[immunization]]s according to current immunization guidelines. Avoid use of live [[vaccine]]s in patients treated with Ixekizumab. No data are available on the response to live or inactive [[vaccine]]s.
|clinicalTrials=The following adverse drug reactions are discussed in greater detail in other sections of the label:
|clinicalTrials=The following adverse drug reactions are discussed in greater detail in other sections of the label:
*Infections
*Infections
Line 100: Line 120:


The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to TALTZ with the incidences of antibodies to other products may be misleading.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to TALTZ with the incidences of antibodies to other products may be misleading.
|alcohol=Alcohol-Ixekizumab interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=Alcohol-Ixekizumab interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
}}
}}

Revision as of 04:58, 26 May 2016

Ixekizumab
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Ixekizumab is a humanized anti-interleukin-17 monoclonal antibody that is FDA approved for the treatment of of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.. Common adverse reactions include injection site reactions, upper respiratory tract infections, nausea, and tinea infections (≥1%)..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Dosage

Ixekizumab is administered by subcutaneous injection. The recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.

Tuberculosis Assessment Prior to Initiation of Ixekizumab

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Ixekizumab.

Important Administration Instructions

There are two presentations for Ixekizumab (i.e., autoinjector and prefilled syringe).

Ixekizumab is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in subcutaneous injection technique using the autoinjector or prefilled syringe. Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis. Administration of Ixekizumab in the upper, outer arm may be performed by a caregiver or healthcare provider.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Preparation for Use of Ixekizumab Autoinjector and Prefilled Syringe

Before injection, remove Ixekizumab autoinjector or Ixekizumab prefilled syringe from the refrigerator and allow Ixekizumab to reach room temperature (30 minutes) without removing the needle cap.

Inspect Ixekizumab formulation visually for particulate matter and discoloration prior to administration. Ixekizumab formulation is a clear and colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow). Ixekizumab formulation does not contain preservatives, therefore discard any unused product remaining in the autoinjector or prefilled syringe.

Instruct patients using the autoinjector or prefilled syringe to inject the full amount (1 mL), which provides 80 mg of Ixekizumab, according to the directions.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ixekizumab in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ixekizumab in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

FDA Package Insert for Ixekizumab contains no information regarding Pediatric Indications and Dosage.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ixekizumab in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ixekizumab in pediatric patients.

Contraindications

Ixekizumab is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Warnings

Infections

Ixekizumab may increase the risk of infection. In clinical trials, the Ixekizumab treated group had a higher rate of infections than the placebo group (27% vs. 23%). Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the Ixekizumab treated group than in the placebo group.

Instruct patients treated with Ixekizumab to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue Ixekizumab until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Ixekizumab. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Ixekizumab. Consider anti-TB therapy prior to initiating Ixekizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving Ixekizumab should be monitored closely for signs and symptoms of active TB during and after treatment.

Hypersensitivity

Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Ixekizumab group in clinical trials. If a serious hypersensitivity reaction occurs, discontinue Ixekizumab immediately and initiate appropriate therapy.

Inflammatory Bowel Disease

Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Ixekizumab group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than the placebo group (0%) during the 12-week, placebo-controlled period. During Ixekizumab treatment, monitor for onset or exacerbation of inflammatory bowel disease.

Immunizations

Prior to initiating therapy with Ixekizumab, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Ixekizumab. No data are available on the response to live or inactive vaccines.

Adverse Reactions

Clinical Trials Experience

The following adverse drug reactions are discussed in greater detail in other sections of the label:

  • Infections
  • Hypersensitivity Reactions
  • Inflammatory Bowel Disease

Clinical Trials Experience

Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Weeks 0 to 12:

Three placebo-controlled trials in subjects with plaque psoriasis were integrated to evaluate the safety of TALTZ compared to placebo for up to 12 weeks. A total of 1167 subjects (mean age 45 years; 66% men; 94% White) with plaque psoriasis received TALTZ (160 mg at Week 0, 80 mg every two weeks [Q2W] for 12 weeks) subcutaneously. In two of the trials, the safety of TALTZ (use up to 12 weeks) was also compared with an active comparator, U.S. approved etanercept.

In the 12-week, placebo-controlled period, adverse events occurred in 58% of the TALTZ Q2W group (2.5 per subject-year of follow-up) compared with 47% of the placebo group (2.1 per subject-year of follow-up). Serious adverse events occurred in 2% of the TALTZ group (0.07 per subject-year of follow-up), and in 2% of the placebo group (0.07 per subject-year of follow-up).

Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the TALTZ group than in the placebo group during the 12-week placebo-controlled period of the pooled clinical trials.

Adverse reactions that occurred at rates less than 1% in the TALTZ group and more frequently than in the placebo group during the 12-week induction period included rhinitis, oral candidiasis, urticaria, influenza, conjunctivitis, inflammatory bowel disease, and angioedema.

Weeks 13 to 60:

A total of 332 subjects received the recommended maintenance regimen of TALTZ 80 mg dosed every 4 weeks.

During the maintenance period (Weeks 13 to 60), adverse events occurred in 80% of subjects treated with TALTZ (1.0 per subject-year of follow-up) compared to 58% of subjects treated with placebo (1.1 per subject-year of follow-up). Serious adverse events were reported in 4% of subjects treated with TALTZ (0.05 per subject-year of follow-up) and none in the subjects treated with placebo.

Weeks 0 to 60:

Over the entire treatment period (Weeks 0 to 60), adverse events were reported in 67% of subjects treated with TALTZ (1.4 per subject-year of follow-up) compared to 48% of subjects treated with placebo (2.0 per subject-year of follow-up). Serious adverse events were reported in 3% of subjects treated with TALTZ (0.06 per subject-year of follow-up), and in 2% of subjects treated with placebo (0.06 per subject-year of follow-up).

Specific Adverse Drug Reactions:

Injection Site Reactions

The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild-to-moderate in severity and did not lead to discontinuation of TALTZ.

Infections

In the 12-week, placebo-controlled period of the clinical trials in plaque psoriasis, infections occurred in 27% of subjects treated with TALTZ (1.2 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.4% of subjects treated with TALTZ (0.02 per subject-year of follow-up) and in 0.4% of subjects treated with placebo (0.02 per subject-year of follow-up).

During the maintenance treatment period (Weeks 13 to 60), infections occurred in 57% of subjects treated with TALTZ (0.70 per subject-year of follow-up) compared to 32% of subjects treated with placebo (0.61 per subject-year of follow-up). Serious infections occurred in 0.9% of subjects treated with TALTZ (0.01 per subject-year of follow-up) and none in the subjects treated with placebo.

Over the entire treatment period (Weeks 0 to 60), infections were reported in 38% of subjects treated with TALTZ (0.83 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.7% of subjects treated with TALTZ (0.02 per subject-year of follow-up), and in 0.4% of subject treated with placebo (0.02 per subject-year of follow-up).

Laboratory Assessment of Cytopenia

Neutropenia

Over the entire treatment period (Weeks 0 to 60), neutropenia occurred in 11% of subjects treated with TALTZ (0.24 per subject-year of follow-up) compared to 3% of subjects treated with placebo (0.14 per subject-year of follow-up). In subjects treated with TALTZ, the incidence rate of neutropenia during Weeks 13 to 60 was lower than the incidence rate during Weeks 0 to 12.

In the 12-week, placebo-controlled period, neutropenia ≥ Grade 3 (<1,000 cells/mm3) occurred in 0.2% of the TALTZ group (0.007 per subject-year of follow-up) compared to 0.1% of the placebo group (0.006 per subject-year of follow-up). The majority of cases of neutropenia were either Grade 2 (2% for TALTZ 80 mg Q2W versus 0.3% for placebo; ≥1,000 to <1,500 cells/mm3) or Grade 1 (7% for TALTZ 80 mg Q2W versus 3% for placebo; ≥1,500 cells/mm3 to ˂2,000 cells/mm3). Neutropenia in the TALTZ group was not associated with an increased rate of infection compared to the placebo group.

Thrombocytopenia

Ninety eight percent of cases of thrombocytopenia were Grade 1 (3% for TALTZ 80 mg Q2W versus 1% for placebo; ≥75,000 cells/mm3 to <150,000 cells/mm3). Thrombocytopenia in subjects treated with TALTZ was not associated with an increased rate of bleeding compared to subjects treated with placebo.

Active Comparator Trials

In the two clinical trials that included an active comparator, the rate of serious adverse events during weeks zero to twelve was 0.7% for U.S. approved etanercept and 2% for TALTZ 80 mg Q2W, and the rate of discontinuation from adverse events was 0.7% for U.S. approved etanercept and 2% for TALTZ 80 mg Q2W. The incidence of infections was 18% for U.S. approved etanercept and 26% for TALTZ 80 mg Q2W. The rate of serious infections was 0.3% for both TALTZ 80 mg Q2W and U.S. approved etanercept.

Immunogenicity

As with all therapeutic proteins there is the potential for immunogenicity with TALTZ. By Week 12, approximately 9% of subjects treated with TALTZ every 2 weeks developed antibodies to ixekizumab. Approximately 22% of subjects treated with TALTZ at the recommended dosing regimen developed antibodies to ixekizumab during the 60-week treatment period. The clinical effects of antibodies to ixekizumab are dependent on the antibody titer; higher antibody titers were associated with decreasing drug concentration and clinical response.

Of the subjects who developed antibodies to ixekizumab during the 60-week treatment period, approximately 10%, which equates to 2% of subjects treated with TALTZ at the recommended dosing regimen, had antibodies that were classified as neutralizing. Neutralizing antibodies were associated with reduced drug concentrations and loss of efficacy.

However, the assay to test for neutralizing antibodies has limitations detecting neutralizing antibodies in the presence of ixekizumab; therefore, the incidence of neutralizing antibodies development could be underestimated.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to TALTZ with the incidences of antibodies to other products may be misleading.

Postmarketing Experience

There is limited information regarding Ixekizumab Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Ixekizumab Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Ixekizumab in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ixekizumab in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ixekizumab during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ixekizumab in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Ixekizumab in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Ixekizumab in geriatric settings.

Gender

There is no FDA guidance on the use of Ixekizumab with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ixekizumab with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ixekizumab in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ixekizumab in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ixekizumab in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ixekizumab in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Ixekizumab Administration in the drug label.

Monitoring

There is limited information regarding Ixekizumab Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Ixekizumab and IV administrations.

Overdosage

There is limited information regarding Ixekizumab overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Ixekizumab Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Ixekizumab Mechanism of Action in the drug label.

Structure

There is limited information regarding Ixekizumab Structure in the drug label.

Pharmacodynamics

There is limited information regarding Ixekizumab Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Ixekizumab Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Ixekizumab Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Ixekizumab Clinical Studies in the drug label.

How Supplied

There is limited information regarding Ixekizumab How Supplied in the drug label.

Storage

There is limited information regarding Ixekizumab Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ixekizumab |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ixekizumab |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Ixekizumab Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Ixekizumab interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Ixekizumab Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Ixekizumab Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.